Related Experiment Videos
Protective effect of liposomal-amphotericin B against C. albicans infection in mice
Abstract:
The efficacy of free amphotericin B (AmpB) and liposomal-amphotericin B (L-AmpB) in the protection against C. albicans infection in mice was studied. Mice injected with a single dose of L-AmpB (1-4 mg/kg) two days prior to the yeast inoculation had an increased survival time when compared to animals injected with lower doses (0.8 mg/kg) of free AmpB or L-AmpB. L-AmpB (4 mg/kg of body weight) conferred protection against the fungal infection even when administered as a single dose five days prior to the yeast inoculation. A single-dose regimen of free AmpB showed a protective effect only when administered two days prior to the inoculum. When mice were challenged with larger yeast inocula, protection was seen with L-AmpB (4 mg/kg) or with multiple doses of free AmpB (0.8 mg/kg daily x 5) and not with single doses of free AmpB. In this group of mice, only animals treated with L-AmpB were microbiologically free of infection.
Insights
Liposomal amphotericin B (L-AmpB) offers superior protection against Candida albicans infections in mice compared to free amphotericin B (AmpB). L-AmpB provides extended survival and complete microbiological clearance, even with delayed or single-dose administration.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Candida albicans is a common fungal pathogen causing opportunistic infections.
- Amphotericin B (AmpB) is a critical antifungal agent, but its use is limited by toxicity.
- Liposomal formulations of AmpB (L-AmpB) aim to improve efficacy and reduce toxicity.
Purpose of the Study:
- To compare the efficacy of free amphotericin B (AmpB) and liposomal amphotericin B (L-AmpB) in a murine model of Candida albicans infection.
- To evaluate the impact of dosing timing and regimen on the protective effects of both AmpB formulations.
Main Methods:
- A murine model was used to assess survival rates and microbiological clearance after infection with Candida albicans.
- Mice were treated with varying doses and schedules of free AmpB and L-AmpB prior to or after yeast inoculation.
- Survival time and fungal burden were measured to determine treatment efficacy.
Main Results:
- Liposomal amphotericin B (L-AmpB) significantly increased survival time compared to free amphotericin B (AmpB) when administered at equivalent or lower doses.
- A single dose of L-AmpB (4 mg/kg) provided protection even when given five days before infection, whereas free AmpB required administration two days prior.
- L-AmpB (4 mg/kg) was effective against larger fungal inocula, leading to complete microbiological eradication, unlike free AmpB regimens.
Conclusions:
- Liposomal amphotericin B demonstrates superior efficacy and a broader therapeutic window than conventional amphotericin B for treating Candida albicans infections in mice.
- L-AmpB offers enhanced protection, improved survival, and complete fungal clearance, highlighting its potential as a more effective antifungal therapy.